Costs and trends in pancreatic cancer treatment

Cancer

Volumn 118, Issue 20, 2012, Pages 5132-5139

  O'Neill, Caitriona B ^a   Atoria, Coral L ^a   O'Reilly, Eileen M ^a   Lafemina, Jennifer ^a   Henman, Martin C ^b   Elkin, Elena B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

adenocarcinoma; and End Results; cost; Epidemiology; health care services; Medicare; pancreas cancer; Surveillance; treatment

Indexed keywords

AGED; ARTICLE; CANCER THERAPY; DISTANT METASTASIS; FEMALE; HEALTH CARE COST; HEALTH SERVICE; HOSPITAL COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; PANCREAS CANCER; PATIENT IDENTIFICATION; PRIORITY JOURNAL; TREND STUDY;

EID: 84867331231     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27490     Document Type: Article

References (54)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. American Cancer Society. Cancer Facts &; Figures 2010. http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-and-figures-2010. Accessed Oct 1, 2011.
3. Stathis A, Moore MJ,. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010; 7: 163-172.
4. Chua YJ, Zalcberg JR,. Pancreatic cancer-is the wall crumbling? Ann Oncol. 2008; 19: 1224-1230.
5. Bayraktar S, Bayraktar UD, Rocha-Lima CM,. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J Gastroenterol. 2010; 16: 673-682.
6. Brown ML, Riley GF, Schussler N, Etzioni R,. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002; 40 (8 suppl):IV-104-117.
7. Chang S, Long SR, Kutikova L, Bowman L, Crown WH, Lyman GH,. Burden of pancreatic cancer and disease progression: economic analysis in the US. Oncology. 2006; 70: 71-80.
8. Du W, Touchette D, Vaitkevicius VK, Peters WP, Shields AF,. Cost analysis of pancreatic carcinoma treatment. Cancer. 2000; 89: 1917-1924.
9. Wilson LS, Lightwood JM,. Pancreatic cancer: total costs and utilization of health services. J Surg Oncol. 1999; 71: 171-181.
10. Elixhauser A, Halpern MT,. Economic evaluations of gastric and pancreatic cancer. Hepatogastroenterology. 1999; 46: 1206-1213.
11. Brown DM, Everhart JE,. Costs of digestive diseases in the United States. In:, Everhart JE, ed. Digestive diseases in the United States: epidemiology and impact. US Department of Health and Human Services, National Institutes of Health. Washington, DC: US Government Printing Office, 1994: 55-82.
12. Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK,. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist. 2003; 8: 541-552.
13. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 (8 suppl): IV-3-18.
14. Simons JP, Ng SC, McDade TP, Zhou Z, Earle CC, Tseng JF,. Progress for resectable pancreatic [corrected] cancer?: a population-based assessment of US practices. Cancer. 2010; 116: 1681-1690.
15. Krzyzanowska MK, Weeks JC, Earle CC,. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol. 2003; 21: 3409-3414.
16. Deyo RA, Cherkin DC, Ciol MA,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45: 613-619.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
18. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML,. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008; 100: 888-897.
19. Riley GF, Potosky AL, Lubitz JD, Kessler LG,. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care. 1995; 33: 828-841.
20. Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Riley GF,. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol. 2002; 20: 307-316.
21. The Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. Table IV. A1. Components of Historical and Projected Increases in HI Inpatient Hospital Payments. In: 2010 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds, p. 154. https://www.cms.gov/ReportsTrustFunds/downloads/tr2010.pdf. Accessed October 26, 2011.
22. Centers for Medicare & Medicaid Services. Quarterly Index Levels in the CMS Medicare Economic Index using IHS Global Insight Inc. (IGI) Forecast Assumptions, by Expense Category:1991-2020. https://www.cms.gov/ MedicareProgramRatesStats/downloads/mktbskt-economic-index.pdf. Accessed October 26, 2011.
23. Centers for Medicare & Medicaid Services. Wage Index Files. Table 4A. https://www.cms.gov/AcuteInpatientPPS/WIFN/itemdetail.asp?filter Type=none&filterByDID=-99&sortByDID=3&sortOrder=ascending& itemID=CMS059968&intNumPerPage=10. Accessed October 26, 2011.
24. Centers for Medicare & Medicaid Services. Wage Index Files. Table 4B. https://www.cms.gov/AcuteInpatientPPS/WIFN/itemdetail.asp?filterType= none&filterByDID=-99&sortByDID= 3&sortOrder=ascending &itemID=CMS059969&intNumPerPage=10. Accessed October 26, 2011.
25. Centers for Medicare & Medicaid Services. Geographic Practice Cost Indices by Medicare Carrier and Locality. https://www.cms.gov/PhysicianFeeSched/ PFSRVF/itemdetail.asp?filterType=none&filterByDID =-99&sortByDID= 1&sortOrder=ascending&itemID=CMS1186375 &intNumPerPage=10. Accessed October 26, 2011.
26. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457-481.
27. Lea MS, Stahlgren LH,. Is resection appropriate for adenocarcinoma of the pancreas? A cost-benefit analysis. Am J Surg. 1987; 154: 651-654.
28. Brandabur JJ, Kozarek RA, Ball TJ, et al. Nonoperative versus operative treatment of obstructive jaundice in pancreatic cancer: cost and survival analysis. Am J Gastroenterol. 1988; 83: 1132-1139.
29. Gudjonsson B,. Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg. 1995; 181: 483-503.
30. Holbrook RF, Hargrave K, Traverso LW,. A prospective cost analysis of pancreatoduodenectomy. Am J Surg. 1996; 171: 508-511.
31. Raikar GV, Melin MM, Ress A, et al. Cost-effective analysis of surgical palliation versus endoscopic stenting in the management of unresectable pancreatic cancer. Ann Surg Oncol. 1996; 3: 470-475.
32. Topal B, Peeters G, Vandeweyer H, Aerts R, Penninckx F,. Hospital cost-categories of pancreaticoduodenectomy. Acta Chir Belg. 2007; 107: 373-377.
33. Enestvedt CK, Mayo SC, Diggs BS, et al. Diagnostic laparoscopy for patients with potentially resectable pancreatic adenocarcinoma: is it cost-effective in the current era? J Gastrointest Surg. 2008; 12: 1177-1184.
34. Jeurnink SM, Polinder S, Steyerberg EW, Kuipers EJ, Siersema PD,. Cost comparison of gastrojejunostomy versus duodenal stent placement for malignant gastric outlet obstruction. J Gastroenterol. 2010; 45: 537-543.
35. Waters JA, Canal DF, Wiebke EA, et al. Robotic distal pancreatectomy: cost effective? Surgery. 2010; 148: 814-823.
36. Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol. 1995; 6: 267-274.
37. Ishii H, Furuse J, Kinoshita T, et al. Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine. Jpn J Clin Oncol. 2005; 35: 526-530.
38. Miksad RA, Schnipper L, Goldstein M,. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol. 2007; 25: 4506-4507.
39. Danese MD, Reyes C, Northridge K, Lubeck D, Lin CY, O'Connor P,. Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer. Clin Ther. 2008; 30: 775-784.
40. Krzyzanowska MK, Earle CC, Kuntz KM, Weeks JC,. Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007; 67: 211-218.
41. Hjelmgren J, Ceberg J, Persson U, Alvegård TA,. The cost of treating pancreatic cancer. Acta Oncol. 2003; 42: 218-226.
42. Müller-Nordhorn J, Brüggenjürgen B, Böhmig M, et al. Direct and indirect costs in a prospective cohort of patients with pancreatic cancer. Aliment Pharmacol Ther. 2005; 22: 405-415.
43. Etzioni R, Urban N, Baker M,. Estimating the costs attributable to a disease with application to ovarian cancer. J Clin Epidemiol. 1996; 49: 95-103.
44. Sheffield KM, Boyd CA, Benarroch-Gampel J, Kuo YF, Cooksley CD, Riall TS,. End-of-life care in medicare beneficiaries dying with pancreatic cancer. Cancer. 2011; 117: 5003-5012.
45. Tangka FK, Trogdon JG, Richardson LC, Howard D, Sabatino SA, Finkelstein EA,. Cancer treatment cost in the United States: has the burden shifted over time? Cancer. 2010; 116: 3477-3484.
46. Riall TS, Lillemoe KD,. Underutilization of surgical resection in patients with localized pancreatic cancer. Ann Surg. 2007; 246: 181-182.
47. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS,. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007; 246: 173-180.
48. Yim HB, Jacobson BC, Saltzman JR, et al. Clinical outcome of the use of enteral stents for palliation of patients with malignant upper GI obstruction. Gastrointest Endosc. 2001; 53: 329-332.
49. Johnsson E, Thune A, Liedman B,. Palliation of malignant gastroduodenal obstruction with open surgical bypass or endoscopic stenting: clinical outcome and health economic evaluation. World J Surg. 2004; 28: 812-817.
50. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010; 363: 733-742.
51. Simons JP, Ng SC, McDade TP, Zhou Z, Earle CC, Tseng JF,. Progress for resectable cancer? Cancer. 2010; 116: 1681-1690.
52. Artinyan A, Anaya DA, McKenzie S, Ellenhorn JD, Kim J,. Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma. Cancer. 2011; 117: 2044-2049.
53. Almhanna K, Philip P,. Defining new paradigms for the treatment of pancreatic cancer. Curr Treat Options Oncol. 2011; 12: 111-125.
54. Huang H, Dong X, Kang MX, et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J Gastroenterol. 2010; 105: 1661-1669.